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tolic blood pressure were examined in the stage 3a and 3b 
CKD subgroups, with greater decreases in HbA 1c , –0.47% 
(–0.61, –0.32) and body weight in subjects in stage 3a CKD, 
–1.8% (–2.3, –1.2) with canagliflozin 100 mg. Initial declines 
in eGFR were seen early following treatment initiation with 
canagliflozin, but trended towards baseline over time. The 
most common adverse events with canagliflozin included 
genital mycotic infections and adverse events related to re-
duced intravascular volume likely secondary to osmotic di-
uresis.  Conclusion: In subjects  with T2DM and stage 3 CKD, 
canagliflozin reduced HbA 1c , body weight, and blood pres-
sure, and was generally well tolerated.  © 2014 S. Karger AG, Basel 
 Introduction 
 Chronic kidney disease (CKD) is a common complica-
tion in patients with type 2 diabetes mellitus (T2DM), 
with up to 30% of patients developing stage 3 or higher 
CKD (estimated glomerular filtration rate (eGFR) <60 
ml/min/1.73 m 2 ) within 15 years of diagnosis  [1, 2] . Man-
agement of T2DM in patients with CKD represents a clin-
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 Abstract 
 Background/Aims: Some sodium glucose co-transporter 2 
(SGLT2) inhibitors are approved for the treatment of patients 
with type 2 diabetes mellitus (T2DM) with an estimated glo-
merular filtration rate (eGFR) of  ≥ 45 ml/min/1.73 m 2 . The ef-
ficacy and safety of canagliflozin, an approved SGLT2 inhibi-
tor, was evaluated in patients with stage 3 chronic kidney 
disease (CKD; eGFR  ≥ 30 to <60 ml/min/1.73 m 2 ).  Methods: 
This analysis used integrated data from four randomized, 
placebo-controlled, phase 3 studies that enrolled patients 
with T2DM and stage 3 CKD. Results are presented for the 
overall population as well as subgroups with stage 3a CKD 
(eGFR  ≥ 45 and <60 ml/min/1.73 m 2 ) and stage 3b CKD (eGFR 
 ≥ 30 and <45 ml/min/1.73 m 2 ).  Results: Among all subjects 
studied with stage 3 CKD, placebo-subtracted reductions in 
HbA 1c (–0.38 and –0.47%; p < 0.001), body weight (–1.6 and 
–1.9%; p < 0.001), and systolic blood pressure (–2.8 and –4.4 
mm Hg; p < 0.01) were seen with canagliflozin 100 and 300 
mg, respectively. Decreases in HbA 1c , body weight, and sys-
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ical challenge with limited treatment options, as most oral 
hypoglycemic agents have decreased efficacy and/or de-
layed clearance as well as more adverse events (AEs) 
among those with stage 3 or higher CKD  [1, 3] . A novel 
class of oral agents, sodium glucose co-transporter 2 
(SGLT2) inhibitors, provide physicians with an addition-
al treatment option for patients with T2DM and stage 3 
CKD.
 The SGLT2 protein, expressed in the proximal tubules 
of the kidney, is responsible for about 90% of glucose re-
absorption filtered through the glomerulus  [4, 5] . Filtered 
glucose is almost fully reabsorbed until the transporters 
reach maximum glucose capacity; the plasma concentra-
tion at which this occurs is referred to as the renal thresh-
old for glucose (RT G ). Above this threshold, urinary glu-
cose excretion increases in proportion to the plasma glu-
cose concentration.
 Canagliflozin is an orally active SGLT2 inhibitor de-
veloped for the treatment of patients with T2DM  [6–13] . 
By inhibiting SGLT2, canagliflozin lowers RT G , resulting 
in increased glycosuria and osmotic diuresis, thus direct-
ly lowering plasma glucose concentrations in patients 
with elevated glucose levels  [9, 14–16] . Increased urinary 
glucose excretion also results in weight loss due to loss of 
calories as well as reductions in blood pressure (BP) like-
ly secondary to the osmotic diuresis. Moreover, while 
canagliflozin lowers RT G in patients with T2DM to ap-
proximately 4.4–5.5 mmol/l (80–100 mg/dl)  [9, 14] , it is 
above the usual threshold for hypoglycemia ( ≤ 3.9 mmol/l 
(70 mg/dl)), hence the risk of hypoglycemia with cana-
gliflozin is relatively low. This paper provides analysis of 
pooled data from  all clinical trials that evaluated the safe-
ty and efficacy of canagliflozin in subjects with T2DM 
and stage 3 CKD.
 Materials and Methods 
 Study Design, Patient Populations, and Treatments 
 Data were pooled from the cohorts enrolled in four random-
ized, placebo-controlled, phase 3 studies of subjects with T2DM 
with a baseline eGFR  ≥ 30 and <60 ml/min/1.73 m 2  [17] . The stud-
ies included in this analysis are summarized in  table 1 and include 
data from the canagliflozin monotherapy study  [18] , a study in 
subjects with T2DM and stage 3 CKD (with baseline eGFR  ≥ 30 and 
<50 ml/min/1.73 m 2 )  [13] , a study in older subjects (aged 55–80) 
 [6] , and the ongoing CANagliflozin cardioVascular Assessment 
Study (CANVAS, interim data provided for regulatory filing)  [19] . 
Due to the lack of a control group, data from subjects in the high 
glycemic subset (HbA 1c >10.0 and  ≤ 12.0%) of the monotherapy 
study were excluded from this analysis.
 Across studies, eligible subjects included men and women with 
T2DM who had inadequate glycemic control at screening while on 
protocol-specified diabetes treatment regimens (diet and exercise 
for the monotherapy study and any approved agent for the other 
three studies). Patient inclusion and exclusion criteria and details 
of the individual study designs have previously been reported  [6, 
13, 18, 19] .
 In CANVAS and the study in older subjects, those meeting en-
rollment criteria entered a 2-week, placebo run-in period prior to 
randomization. In the monotherapy and stage 3 CKD studies, sub-
jects who were not on protocol-specified background diabetes 
therapy or were on an anti-hyperglycemic agent (AHA) regimen 
not consistent with local prescribing information at screening, re-
spectively, entered an AHA adjustment (or washout for the mono-
therapy study)/dose stable period prior to the placebo run-in pe-
riod to meet study-specific criteria. In each study, subjects were 
 Table 1.  Study design and subject descriptiona
Study Durationb,
week
 Inclusion criteria Subjects contributing data to 
pooled analysis, n







Monotherapy 26 ≥18 to ≤80 ≥7.0, ≤10.0 ≥50 10 10 12 32
CANagliflozin cardioVascular
Assessment Study (CANVAS) 18 ≥30 ≥7.0, ≤10.5 ≥30 252 208 246 706
Stage 3 CKD population 26 ≥25 ≥7.0, ≤10.5 ≥30, <50 85 87 81 253
Older adults 26 ≥55 to ≤80 ≥7.0, ≤10.0 ≥50 35 33 26 94
Overall total, n 382 338 365 1,085
 PBO = Placebo; CANA = canagliflozin.
a Key exclusion criteria in common across the studies included repeated FPG >15.0 mmol/l (270 mg/dl) in general during the pre-
treatment phase; history of T1DM, CV disease (including myocardial infarction, unstable angina, revascularization procedure, or cere-
brovascular accident) within 3 months prior to screening; or alanine aminotransferase (ALT) level >2.0 times the upper limit of normal 
(ULN) or total bilirubin >1.5 the ULN at screening. b Primary efficacy assessment time point.
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randomly assigned to receive once daily oral doses of canagliflozin 
100 or 300 mg or placebo. In all studies, randomization was strat-
ified to ensure adequate distribution of specific patient character-
istics across treatment groups as previously reported  [6, 13, 18, 19] . 
HbA 1c , fasting plasma glucose (FPG), and postprandial glucose 
values were masked to study centers following randomization un-
less HbA 1c and FPG values met pre-specified glycemic criteria for 
initiation of rescue therapy. Databases were locked at the primary 
assessment time point for each study, and studies were unblinded 
by the sponsor for regulatory filing; subjects and study center and 
local sponsor personnel remained blinded through completion of 
the respective double-blind treatment periods of each study.
 Patients were to remain on stable diabetes treatment (diet/ex-
ercise and AHA regimen) throughout the double-blind treatment 
period. Those meeting pre-specified glycemic criteria were pro-
vided with rescue therapy (with metformin, monotherapy study, 
and uptitration of current AHAs or stepwise addition of other 
AHAs for CANVAS and studies in stage 3 CKD subjects and older 
subjects). In general, during the double-blind treatment period, 
glycemic rescue therapy was initiated if FPG >15.0 mmol/l (270 
mg/dl) after day 1 to week 6, >13.3 mmol/l (240 mg/dl) after week 6 
to week 12, and >11.1 mmol/l (200 mg/dl) after week 12 to week 
26. For CANVAS, patient’s glycemic goals and the need for adjust-
ment in the AHA regimen were to be determined by the investiga-
tor after week 18. The mean duration of drug exposure in this tri-
al was approximately 36 weeks, slightly longer in the canagliflozin 
groups compared to placebo.
 All studies included in this analysis were conducted in accor-
dance with ethical principles that comply with the Declaration of 
Helsinki and are consistent with Good Clinical Practice and ap-
plicable regulatory requirements. Institutional review boards at 
participating institutions approved study protocols and amend-
ments. All subjects provided written informed consent prior to 
participation.
 Study Endpoints and Assessments 
 Efficacy endpoints were evaluated at the primary assessment 
time point for each study (week 26 for the 3 studies and week 18 for 
CANVAS). Endpoints included change from baseline in HbA 1c and 
the proportion of subjects achieving HbA 1c <7.0%; change from 
baseline in FPG and systolic and diastolic BP; percent change from 
baseline in body weight (reported for data prior to rescue therapy).
 Safety analyses included data up to week 26 for the monother-
apy, stage 3 CKD, and older cohort studies, and a cutoff date of at 
least 18 weeks for CANVAS. Overall safety and tolerability were 
evaluated based on AE reports, safety laboratory tests, 12-lead elec-
trocardiograms, vital sign measurements, self-monitored blood 
glucose, and physical examinations. Specific attention was given to 
AEs related to osmotic diuresis and reduced intravascular volume 
that may be associated with lower eGFR values. Pre-specified que-
ries were constructed for each of these AEs using lists of Medical 
Dictionary for Regulatory Activities (MedDRA) preferred terms 
consistent with the AE of interest; terms associated with each AE 
were grouped for analysis.
 Documented hypoglycemia episodes, including biochemically 
documented episodes (concurrent fingerstick or plasma glucose 
 ≤ 3.9 mmol/l (70 mg/dl) irrespective of symptoms) and severe hy-
poglycemia episodes (i.e. requiring the assistance of another indi-
vidual or resulting in seizure or loss of consciousness), were also 
evaluated. Given the potential effect of background AHAs on the 
risk of hypoglycemia, incidences of documented hypoglycemia are 
reported separately for subjects who were, or were not, on back-
ground AHA therapy associated with hypoglycemia (e.g. insulin, 
sulfonylureas).
 Percent changes from baseline in fasting plasma lipids (i.e. tri-
glycerides, low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), LDL-C/HDL-C ratio, 
and non–HDL-C) were evaluated. Laboratory safety assessments 
included blood chemistry (e.g. serum creatinine, eGFR), hematol-
ogy, urinalysis, and urine albumin/creatinine ratio (ACR). Data 
for change in urine ACR are reported for the individual studies in 
subjects with stage 3 CKD and CANVAS. For evaluation of other 
clinical laboratory analyses, the proportion of subjects meeting 
predefined limits of change criteria was assessed based on any 
post-baseline measurement and on the last on-treatment measure-
ment (defined as the last value within 2 days after the last dose of 
study medication).
 Statistical Methods 
 Efficacy analyses were conducted using the modified intent-to-
treat population, which consisted of all randomized subjects who 
received  ≥ 1 dose of study drug, according to the randomized treat-
ment assignment. The last observation carried forward (LOCF) 
approach was used to impute missing efficacy data. If subjects re-
ceived rescue therapy, all post-rescue data were censored and the 
last post-baseline value prior to the initiation of rescue therapy was 
used for analyses. Continuous efficacy endpoints were assessed us-
ing an analysis of covariance (ANCOVA) model with treatment 
and study as factors and the respective baseline value as a covariate. 
Least squares (LS) mean differences and two-sided 95% confidence 
intervals (CIs) were estimated based on this model for the com-
parison of each canagliflozin group versus placebo with no multi-
plicity adjustment.
 A sensitivity analysis of the change from baseline in HbA 1c was 
also performed using the completers analysis set (i.e. subjects in 
the pooled population who completed the study through the pri-
mary assessment time point) using the same analysis approach. 
The categorical efficacy endpoint (i.e. proportion of subjects 
achieving HbA 1c goals) was analyzed using a logistic regression 
model with treatment and study as factors and baseline HbA 1c as 
covariate.
 Safety analyses were performed in randomized subjects who 
received  ≥ 1 dose of study drug. All AEs and lipids parameters are 
reported for regardless of rescue therapy; documented hypoglyce-
mia episodes are reported for prior to rescue medication.
 Results 
 Baseline Characteristics 
 The baseline demographic characteristics were similar 
among the treatment arms as listed in  table 2 . While the 
data represent a cross section of ethnic groups, there are 
lower percentages of some groups. Nevertheless, across 
all phase 3 studies in the canagliflozin program (n = 
10,285 randomized subjects who had taken at least one 
dose of the study medication), the majority of the Black 
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or African-American subjects were recruited from the 
USA and represent approximately 14% (359/2634) of the 
subjects randomized from the USA, consistent with the 
proportion having T2DM in the USA in this population. 
Note that the studies discussed in this analysis did not 
mandate a pre-specified breakdown of racial and ethnic 
representation, however the data are consistent with the 
proportion of African-Americans having T2DM in the 
USA.
 Evaluation of subgroups based on eGFR showed that 
those with stage 3b CKD were older and had a longer 
mean duration of T2DM as compared to those with stage 
3a CKD, although HbA 1c was similar in both subgroups 
(online suppl. table 1; for all online suppl. material, see 
www.karger.com/doi/10.1159/000364909). Those with 
stage 3a CKD had a mean ± SD baseline eGFR of 53.3 ± 
4.2 ml/min/1.73 m 2 compared to those with stage 3b CKD 
who had a mean GFR of 38.2 ± 4.1 ml/min/1.73 m 2 . Over-
all, 90.1% of subjects were receiving either an angioten-
sin-converting enzyme (ACE) inhibitor, angiotensin re-
ceptor blocker (ARB), or a diuretic; 88.1% of those with 
stage 3a CKD were on these medications, as were 94.2% 
of those with stage 3b CKD.
 Efficacy
Total Cohort of Subjects with Stage 3 CKD 
 In the overall cohort of subjects with stage 3 CKD, sig-
nificant reductions in HbA 1c were seen with canagliflozin 
100 and 300 mg relative to placebo (LS mean differences 
(95% CI) of –0.38% (–0.50, –0.26) and –0.47% (–0.60, 
–0.35), respectively; p < 0.001;  fig. 1 a). Results of the sen-
sitivity analysis using the completers analysis set showed 








Male 226 (59) 198 (59) 210 (58)
Female 156 (41) 140 (41) 155 (42)
Mean age ± SD, years 66.9±7.6 67.3±8.1 66.9±7.4
Race, n (%)a
White 309 (81) 260 (77) 280 (77)
Black or African-Americanb 9 (2) 9 (3) 13 (4)
Asian 50 (13) 43 (13) 48 (13)
Otherc 14 (4) 26 (8) 24 (7)
Mean body mass index ± SD, kg/m2 33.0±6.2 32.2±6.1 32.3±6.1
Mean triglycerides ± SD, mmol/l 2.1±1.3 2.0±1.1 2.0±1.0
Mean LDL-C ± SD, mmol/l 2.4±0.9 2.3±0.9 2.3±1.0
Mean eGFR ± SD, ml/min/1.73 m2 48.8±8.0 48.0±8.5 47.8±8.2
Mean ACR ± SD, g/mol 23.3±63.0 20.1±51.8 26.4±87.1
Mean potassium ± SD, mEq/l 4.6±0.5 4.5±0.5 4.6±0.6
Mean duration of T2DM ± SD, years 15.0±9.0 15.0±7.9 15.4±8.3
Daily cigarette smoker at study entry, n (%) 45 (11.8) 32 (9.5) 33 (9.0)
Patients on AHA at baseline, n (%) 365 (95.5) 321 (95.0) 346 (94.8)
Biguanided 147 (38.5) 111 (32.8) 107 (29.3)
Sulfonyluread 160 (41.9) 128 (37.9) 141 (38.6)
Insulind 219 (57.3) 208 (61.5) 221 (60.5)
Patients on antihypertensive medication at baseline, n (%)e 345 (90.3) 307 (90.8) 326 (89.3)
ACE inhibitor 191 (50.0) 146 (43.2) 164 (44.9)
ARB 131 (34.3) 120 (35.5) 121 (33.2)
ACE inhibitor + ARB 18 (4.7) 20 (5.9) 17 (4.7)
ACE inhibitor + diuretic 8 (2.1) 18 (5.3) 12 (3.3)
ARB + diuretic 14 (3.7) 16 (4.7) 20 (5.5)
 PBO = Placebo; CANA = canagliflozin.
a Percentages may not total 100% due to rounding. b Black/African-American patients represent 10% (30/299) of patients with stage 
3 CKD from the USA. c Includes American-Indian or Alaska Native, Native Hawaiian or other Pacific Islanders, multiple, other, not 
reported, and unknown. d Alone or in combination with other AHAs. e ACE inhibitor or ARB or diuretic.
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similar placebo-subtracted LS mean changes (95% CI) of 
–0.31% (–0.44, –0.19) and –0.41% (–0.53, –0.28) with 
canagliflozin 100 and 300 mg, respectively; p < 0.001. The 
proportion of subjects achieving HbA 1c <7.0% was higher 
with canagliflozin 100 and 300 mg compared with pla-
cebo (24.5, 31.9, and 17.4%, respectively; p < 0.001 for 
canagliflozin 300 mg vs. placebo). Canagliflozin 100 and 
300 mg were also associated with reductions in FPG 
 relative to placebo (LS mean differences (95% CI) of –1.1 
mmol/l (–1.4, –0.7) and –1.2 mmol/l (–1.6, –0.9), respec-
tively; –18.8 mg/dl (–25.4, –12.4) and –22.0 mg/dl (–28.4, 
–15.6), respectively; p < 0.001).
 There is no formal comparison of the glucose-lower-
ing effect of canagliflozin between those with an eGFR 
>60 ml/min/1.73 m 2 and those with stage 3 CKD. Glyce-
mic efficacy, however, was demonstrated in subjects with 
CKD stage 3 renal disease ( fig. 2 ), albeit with a lesser ex-
tent of glucose lowering than seen in subjects with stages 
1 or 2 CKD. Nonetheless, canagliflozin got more subjects 
with stage 3 CKD to the glycemic goal (HbA 1c <7%). The 
changes in HbA 1c are not confounded since these patients 
did not have anemia given baseline hemoglobin values 
13.45, 13.44 and 13.54 g/dl in the placebo, canagliflozin 
100- and 300-mg groups, respectively.
 Body weight was significantly reduced in the overall 
population of subjects with stage 3 CKD with cana-
gliflozin 100 and 300 mg compared with placebo (LS 
mean (placebo-subtracted) differences (95% CI) of –1.6% 
(–2.0, –1.1) and –1.9% (–2.3, –1.5), respectively; –1.4 kg 
(–1.8, –1.0) and –1.8 kg (–2.1, –1.4), respectively; p < 
0.001;  fig. 1 b). Canagliflozin 100 and 300 mg were also 
associated with reductions in systolic BP relative to pla-
cebo (LS mean differences (95% CI) of –2.8 mm Hg (–4.7, 
–0.8) and –4.4 mm Hg (–6.3, –2.4), respectively;  fig. 1 c). 
Generally, only minimal changes in fasting plasma lipids 
were observed with canagliflozin 100 and 300 mg com-
pared with placebo (online suppl. table 2).
 Stage 3a CKD Subgroup 
 In the subgroup of subjects with stage 3a CKD, place-
bo-subtracted LS mean reductions (95% CI) in HbA 1c 
were –0.47% (–0.61, –0.32) and –0.52% (–0.67, –0.38) 
with canagliflozin 100 and 300 mg, respectively (online 
suppl. table  3). The proportion of subjects achieving 
HbA 1c <7.0% was 26.0, 32.8 and 19.4% with canagliflozin 
100 and 300 mg and placebo, respectively. Placebo-sub-
tracted LS mean reductions (95% CI) in FPG were also 
seen with canagliflozin 100 mg (–1.2 mmol/l (–1.6, –0.8); 
 Fig. 1. Changes in ( a ) HbA 1c , ( b ) body weight, and ( c ) systolic BP for the overall stage 3 CKD population. SE = Standard error; PBO = 
placebo; CANA = canagliflozin. Note: Statistical comparison for changes in systolic BP with CANA 100 and 300 mg vs. PBO not per-
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–21.8 mg/dl (–29.4, –14.2)) and 300 mg (–1.3 mmol/l 
(–1.7, –0.9); –23.0 mg/dl (–30.4, –15.6)).
 Placebo-subtracted LS mean percent reductions (95% 
CI) in body weight were –1.8% (–2.3, –1.2) and –2.0% 
(–2.5, –1.5) with canagliflozin 100 and 300 mg, respec-
tively (online suppl. table 3). Placebo-subtracted LS mean 
reductions (95% CI) in systolic BP of –1.8 mm Hg (–4.1, 
0.5) and –4.3 mm Hg (–6.5, –2.0) with canagliflozin 100 
and 300 mg, respectively, were seen in stage 3a CKD sub-
jects (online suppl. table 3). Changes in fasting plasma lip-
ids were generally similar in the stage 3a CKD subgroup 
compared with the overall population, with the exception 
of larger percent increases in LDL-C with canagliflozin 
versus placebo in this subgroup (online suppl. table 4).
 Stage 3b CKD Subgroup 
 Placebo-subtracted LS mean reductions (95% CI) in 
HbA 1c in the stage 3b CKD subgroup were –0.23% (–0.45, 
–0.01) and –0.39% (–0.61, –0.17) with canagliflozin 100 
and 300 mg, respectively. With canagliflozin 100 and 300 
mg and placebo, 22.0, 30.3 and 13.0% of subjects, respec-
tively, achieved HbA 1c <7.0%. Reductions in FPG were 
observed with canagliflozin 100 and 300 mg relative to 
placebo (LS mean differences (95% CI) of –0.7 mmol/l 
(–1.4, –0.02) and –1.1 mmol/l (–1.8, –0.4), respectively; 
–12.8 mg/dl (–25.2, –0.4) and –19.6 mg/dl (–32.1, –7.2), 
respectively).
 Canagliflozin 100 and 300 mg were associated with re-
ductions in body weight compared with placebo (place-
bo-subtracted LS mean percent reductions (95% CI) of 
–1.2% (–1.9, –0.5) and –1.8% (–2.5, –1.1), respectively; 
online suppl. table 3). Placebo-subtracted LS mean reduc-
tions (95% CI) in systolic BP with canagliflozin 100 and 
300 mg were similar in the stage 3b CKD subgroup (–4.8 
mm Hg (–8.5, –1.2) and –4.9 mm Hg (–8.5, –1.2), respec-
tively; online suppl. table 3) compared with the overall 
population. Compared to placebo, both doses of cana-
gliflozin showed reductions in LDL-C, LDL-C/HDL-C 
ratio, and non–HDL-C and increases in HDL-C. A rela-
tive decrease in triglycerides was seen with canagliflozin 
100 mg and an increase with canagliflozin 300 mg (online 
suppl. table 4).
 Safety and Tolerability 
 There was a higher incidence of AEs in those taking 
canagliflozin compared with placebo in the overall popu-
lation as well as the stage 3a and 3b CKD subgroups (table 
3 and online suppl. table 5), however there were more se-
rious AEs in the placebo group. In general, more subjects 
receiving canagliflozin 300 mg had to discontinue the 
drug due to AEs compared to those receiving canagliflozin 
100 mg and placebo. In subjects with stage 3b CKD, how-
ever, AE-related discontinuation rates were higher in 
both canagliflozin dose groups compared with placebo 
(online suppl. table 5). The higher rate of discontinuation 
in those receiving 300 mg was primarily related to AEs 
associated with reduced intravascular volume such as 
postural dizziness and hypotension as well as early and 
reversible reductions in eGFR.
 In the overall CKD cohort, the incidence of AEs related 
to osmotic diuresis, including increased urine output and/
or frequency, and thirst, was similar across groups, and 
 Fig. 2. Comparison of placebo-subtracted 
effect of canagliflozin in people with stages 
1 and 2 CKD versus stage 3 CKD. Data tak-
en from online supplementary table 3 and 
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did not lead to study discontinuation. Reduced intravas-
cular volume-related AEs, such as postural dizziness and 
orthostatic hypotension, were seen more frequently in the 
canagliflozin 100- and 300-mg groups compared with the 
placebo group. The incidence of urinary tract infections 
(UTIs) was slightly higher with canagliflozin 300 mg ver-
sus canagliflozin 100 mg and placebo, without an ob-
served increase in rate of upper UTIs across groups. An 
increased incidence of genital mycotic infections in males 
and females was seen with canagliflozin versus placebo; 
these AEs generally did not lead to study discontinuation. 
No notable differences in the incidence of these specific 
 Table 3.  Summary of overall safety and selected AEs (total stage 3 CKD cohort)a
Patients, n (%) PBO (n = 382) CANA 100 mg (n = 338) CANA 300 mg (n = 365)
Any AE 269 (70.4) 250 (74.0) 275 (75.3)
AEs leading to discontinuation 22 (5.8) 19 (5.6) 28 (7.7)
AEs related to study drugb 82 (21.5) 96 (28.4) 119 (32.6)
Serious AEs 75 (19.6) 45 (13.3) 54 (14.8)
Deaths 6 (1.6) 3 (0.9) 5 (1.4)
Canagliflozin mechanism-related AE
Osmotic diuresis-related AEsc 14 (3.7) 14 (4.1) 14 (3.8)
Serious AEs 0 0 0
Events leading to discontinuation 0 0 0
Volume-related AEsd 10 (2.6) 17 (5.0) 31 (8.5)
Serious AEs 5 (1.3) 1 (0.3) 3 (0.8)
Events leading to discontinuation 0 1 (0.3) 2 (0.5)
Renal-related AEse 14 (3.7) 30 (8.9) 34 (9.3)
Serious AEs 5 (1.3) 4 (1.2) 5 (1.4)
Events leading to discontinuation 4 (1.0) 4 (1.2) 6 (1.6)
Urinary tract infection 23 (6.0) 21 (6.2) 27 (7.4)
Serious AEs 3 (0.8) 1 (0.3) 0
Events leading to discontinuation 2 (0.5) 1 (0.3) 0
Female genital mycotic infectionf,g 3 (1.9) 15 (10.7) 16 (10.3)
Serious AEs 0 0 0
Events leading to discontinuation 0 1 (0.7) 1 (0.6)
Male genital mycotic infectiong,h 3 (1.3) 5 (2.5) 15 (7.1)
Serious AEs 0 0 0
Events leading to discontinuation 0 0 2 (1.0)
AEs reported in ≥2% of patients and ≥0.5% higher with any CANA group vs. PBO
Constipation 7 (1.8) 8 (2.4) 10 (2.7)
Diarrhea 21 (5.5) 9 (2.7) 24 (6.6)
Chest pain 7 (1.8) 5 (1.5) 9 (2.5)
Fatigue 8 (2.1) 9 (2.7) 8 (2.2)
Gastroenteritis 5 (1.3) 7 (2.1) 2 (0.5)
Blood urea increased 6 (1.6) 7 (2.1) 12 (3.3)
Back pain 12 (3.1) 11 (3.3) 13 (3.6)
Osteoarthritis 6 (1.6) 7 (2.1) 4 (1.1)
Pain in extremity 6 (1.6) 11 (3.3) 8 (2.2)
Headache 10 (2.6) 16 (4.7) 9 (2.5)
Dyspnea 6 (1.6) 8 (2.4) 2 (0.5)
Rash 5 (1.3) 4 (1.2) 8 (2.2)
Skin ulcer 2 (0.5) 9 (2.7) 5 (1.4)
 PBO = Placebo; CANA = canagliflozin.
a All AEs are reported for regardless of rescue medication. b Possibly, probably, or very likely related to study drug, as assessed by 
investigators. c Including micturition urgency, nocturia, pollakiuria, polyuria, urine output increased, dry mouth, and thirst. d Including 
dehydration, dizziness postural, hypotension, orthostatic hypotension, presyncope, and syncope. eIncluding blood creatinine increased, 
GFR decreased, oliguria, renal failure, renal failure acute, and renal impairment. f PBO, n = 156; CANA 100 mg, n = 140; CANA 300 
mg, n = 155. g AE included in the grouped terms are not reported. h PBO, n = 226; CANA 100 mg, n = 198; CANA 300 mg, n = 210.
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AEs from placebo were seen in subjects with stage 3a 
CKD. In subjects with stage 3b CKD, however, there was 
a higher incidence of side effects related to volume deple-
tion and UTIs in the canagliflozin 300-mg group (online 
suppl. table 5) compared with the overall cohort.
 Hypoglycemia 
 The incidence and severity of hypoglycemia varied de-
pending on background AHA therapy. Of the 88.2% of 
subjects in the overall population treated with insulin 
and/or a sulfonylurea, 41.9 and 43.8% in the canagliflozin 
100- and 300-mg groups, respectively, experienced hypo-
glycemia episodes documented by decreases in plasma 
glucose to  ≤ 3.9 mmol/l (70 mg/dl), as compared to 29.2% 
in the placebo group. There were 20 subjects who experi-
enced severe hypoglycemia episodes (4 (1.2%) with pla-
cebo, 9 (3%) with canagliflozin 100 mg, and 7 (2.2%) with 
canagliflozin 300 mg). Of those who were not on insulin 
and/or a sulfonylurea, the incidence of hypoglycemia was 
low, with documented (based on plasma glucose) hypo-
glycemia reported in 1 patient (2%) in the placebo group, 
3 (8.1%) in the canagliflozin 100-mg group, and 1 (2.4%) 
in the canagliflozin 300-mg group. There were no severe 
hypoglycemic episodes among subjects not taking insulin 
and/or a sulfonylurea.
 Assessment of Kidney Function 
 Changes in eGFR with canagliflozin in the overall co-
hort demonstrated a small initial decline followed by re-
turn towards trend to baseline ( fig.  3 ) (the changes in 
eGFR for stages 3a and 3b CKD are provided in online 
suppl. fig.  1). These changes suggest an early hemody-
namic effect, seen within days of treatment followed by 
attenuation over time. When endpoint analyses were per-
formed in the overall population, mean eGFR decreased 
by –1.7 and –2.2 ml/min/1.73 m 2 in those treated with 
canagliflozin 100 and 300 mg, respectively, while it rose 
by 0.7 ml/min/1.73 m 2 in the placebo group. Similar mean 
changes were seen with canagliflozin 100 and 300 mg 
compared with placebo at week 26 in the stage 3a CKD 
subgroup (–1.4, –2.3, and 1.0 ml/min/1.73 m 2 , respective-
ly) and the stage 3b CKD subgroup (–2.4, –2.1, and 0.01 
ml/min/1.73 m 2 , respectively).
 In the dedicated study of subjects with stage 3 CKD 
( table 1 ), 29 subjects with macroalbuminuria at baseline 
(>300 μg/mg; 14 in the placebo group, 7 in the cana-
gliflozin 100-mg group and 8 in the canagliflozin 300-mg 
group), showed mean percent reductions (SD) in albu-
minuria of –19.6 (47.3), –53.1 (17.4), and –44.7 (36.0)%, 
respectively.
 The incidence of kidney-associated AEs (e.g. increased 
serum creatinine, decreased eGFR, renal failure, and kid-
ney function impairment) were higher with canagliflozin 
than with placebo ( table 3 ) and generally higher in those 
with stage 3b CKD (online suppl. table 5). In the overall 
population, the most common specific terms for renal 
AEs in the pooled canagliflozin group were blood creati-
nine increased (5.3%), renal impairment (2.4%), and GFR 
decreased (1.3%).
 Changes in Serum Potassium 
 No significant changes in mean serum potassium were 
seen with canagliflozin 100 and 300 mg compared with 
placebo in the overall population (–0.01, 0.07, and 0.02 
mEq/l (mmol/l), respectively), the stage 3a CKD sub-
group (0.05, 0.10, and 0 mEq/l (mmol/l), respectively), or 
 Fig. 3. Changes in eGFR among all stage 3 
CKD participants. PBO = Placebo; CANA = 
canagliflozin; SE = standard error. Note: 
Data are reported regardless of rescue med-
ication and up to within 2 days after the last 
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the stage 3b CKD subgroup (–0.12, 0.02, and 0.07 mEq/l 
(mmol/l), respectively). Based on any post-baseline value, 
the proportion of subjects experiencing increased serum 
potassium above the upper limit of normal and >15% in-
crease from baseline with placebo, canagliflozin 100 and 
300 mg was 7.9, 7.2, and 12.0%, respectively, in the over-
all population; 5.5, 5.2, and 9.1%, respectively, in the stage 
3a CKD subgroup, and 13.5, 10.9, and 17.4%, respective-
ly, in the stage 3b CKD subgroup. When assessed based 
on the last post-baseline value, fewer subjects had an in-
crease in serum potassium above the upper limit of nor-
mal and >15% increase from baseline in the overall popu-
lation (3.0, 1.8 and 3.1%, in the placebo, canagliflozin 
100- and 300-mg groups, respectively), the stage 3a CKD 
subgroup (3.1, 1.9, and 1.7%, respectively), and the stage 
3b CKD subgroup (2.7, 1.7, and 5.8%, respectively). Few 
subjects had any post-baseline potassium elevations that 
were  ≥ 6.5 mEq/l with canagliflozin 100 and 300 mg and 
placebo in the overall population (1.1, 0.9, and 2.3%, re-
spectively), the stage 3a CKD subgroup (0.8, 0, and 1.3%, 
respectively), and the stage 3b CKD subgroup (1.8, 2.5, 
and 4.1%, respectively).
 Phosphate 
 Using post-baseline data the proportion of subjects with 
increasing serum phosphate levels above the upper limit of 
normal and >25% increase from baseline with placebo, 
canagliflozin 100 and 300 mg was 0.3, 2.7, and 5.1%, respec-
tively. When assessed based on the last post-baseline value, 
fewer subjects had an increase in serum phosphate above 
the upper limit of normal and >25% increase from base-
line in the overall population (0, 0.6 and 1.4%, in the pla-
cebo, canagliflozin 100- and 300-mg groups, respectively).
 Serious AEs related to elevated potassium were report-
ed in 3 subjects (1 with canagliflozin 100 mg and 2 with 
canagliflozin 300 mg), all receiving multiple antihyper-
tensive agents affecting potassium homeostasis. All three 
serious events coincided with an acute event, e.g. renal 
failure, and two led to study discontinuation, both with 
canagliflozin 300 mg.
 Discussion 
 We evaluated the effects of canagliflozin in a pooled 
analysis of four randomized, placebo-controlled trials in-
volving T2DM subjects with stage 3 CKD. Canagliflozin 
improved glycemic control in subjects with stage 3 CKD, 
with a greater effect observed in subjects with stage 3a 
CKD. Mean reductions in stage 3b CKD were smaller, 
however, still more subjects achieved an HbA 1c goal of 
<7.0% compared to placebo.
 Canagliflozin 100 mg once daily is recommended for 
use in management of T2DM in subjects with an eGFR of 
45 to <60 ml/min/1.73 m 2  [20] . In the USA, canagliflozin 
100 mg can be initiated in subjects with an eGFR  ≥ 45 ml/
min/1.73 m 2 . In Europe, patients must have baseline 
eGFR   ≥ 60 ml/min/1.73 m 2 to initiate canagliflozin thera-
py; however, patients whose eGFR falls persistently to <60 
ml/min/1.73 m 2 can continue treatment with canagliflozin 
100 mg unless eGFR falls below 45 ml/min/1.73 m 2 .
 The mechanism of canagliflozin action results in an 
osmotic diuresis and caloric loss, which contributes to 
both weight loss and BP reduction. BP control is a major 
concern in patients with stage 3 CKD and hypertension 
is one of the most important risk factors that influences 
CKD progression, as well as the risk of cardiovascular 
events. Canagliflozin reduces BP in those with stage 3 
CKD, further enhancing systolic BP reduction by an ad-
ditional 3–7 mm Hg on top of renin-angiotensin system 
blocking therapy and diuretics  [21] .
 Reduced intravascular volume and decreased eGFR 
were also observed in patients with stage 3 CKD, mostly 
within the first months of treatment and, in a small sub-
group, resulted in drug discontinuation or other antihy-
pertensive drug modification. A dose-dependent increase 
in AEs related to reduced intravascular volume was seen 
with canagliflozin in the CKD cohort. Initial declines in 
eGFR of 10–15% trended toward baseline after about 
6 weeks. These changes are likely due to hemodynamic ef-
fects on the kidney, and do not suggest progressive renal 
injury in subjects with stage 3 CKD. By blocking SGLT2-
dependent glucose reabsorption, SGLT2 inhibitors such 
as canagliflozin are expected to increase the sodium con-
centration in the proximal convoluted tubule, thereby ac-
tivating tubuloglomerular feedback, leading to a decrease 
in hyperfiltration in preclinical models and clinical stud-
ies of diabetes  [22, 23] . Small increases in LDL-C have been 
associated with canagliflozin treatment  [6–8, 10–13, 18] . 
The mechanism for this is not completely understood. In 
the current analysis, percent increases in LDL-C were seen 
with canagliflozin 100 and 300 mg compared with placebo 
in the overall population and the stage 3a CKD subgroup, 
but decreases in LDL-C were seen in the stage 3b CKD sub-
group. This is likely related to the greater increase in LDL-
C in the placebo group in the stage 3b CKD subgroup.
 An increase in UTIs and genital mycotic infections has 
been previously reported  [24] . In the overall population, 
the incidence of UTIs was slightly higher with cana-
gliflozin 300 mg versus canagliflozin 100 mg and placebo; 




 1 Inzucchi SE, Bergenstal RM, Buse JB, Diamant 
M, Ferrannini E, Nauck M, Peters AL, Tsapas 
A, Wender R, Matthews DR: Management of 
hyperglycemia in type 2 diabetes: a patient-
centered approach: position statement of the 
American Diabetes Association (ADA) and the 
European Association for the Study of Diabetes 
(EASD). Diabetes Care 2012; 35: 1364–1379. 
 2 Koro CE, Lee BH, Bowlin SJ: Antidiabetic 
medication use and prevalence of chronic 
kidney disease among patients with type 2 di-
abetes mellitus in the United States. Clin Ther 
2009; 31: 2608–2617. 
 3 Reilly JB, Berns JS: Selection and dosing of 
medications for management of diabetes in 
patients with advanced kidney disease. Semin 
Dial 2010; 23: 163–168. 
 4 Bailey CJ: Renal glucose reabsorption inhibi-
tors to treat diabetes. Trends Pharmacol Sci 
2011; 32: 63–71. 
 5 Nair S, Wilding JP: Sodium glucose co-trans-
porter 2 inhibitors as a new treatment for dia-
betes mellitus. J Clin Endocrinol Metab 2010; 
 95: 34–42. 
 6 Bode B, Stenlof K, Sullivan D, Fung A, Usiskin 
K: Efficacy and safety of canagliflozin treat-
ment in older subjects with type 2 diabetes 
mellitus: a randomized trial. Hosp Pract 
(1995) 2013; 41: 72–84. 
 7 Cefalu WT, Leiter LA, Yoon KH, Arias P, Ni-
skanen L, Xie J, Balis DA, Canovatchel W, 
Meininger G: Efficacy and safety of cana-
gliflozin versus glimepiride in patients with 
type 2 diabetes inadequately controlled with 
metformin (CANTATA-SU): 52-week results 
from a randomised, double-blind, phase 3 
non-inferiority trial. Lancet 2013; 382: 941–
950. 
 8 Lavalle-Gonzalez FJ, Januszewicz A, Davidson 
J, Tong C, Qiu R, Canovatchel W, Meininger 
G: Efficacy and safety of canagliflozin com-
pared with placebo and sitagliptin in patients 
with type 2 diabetes on background metfor-
min monotherapy: a randomised trial. Diabe-
tologia 2013; 56: 2582–2592. 
 9 Rosenstock J, Aggarwal N, Polidori D, Zhao Y, 
Arbit D, Usiskin K, Capuano G, Canovatchel 
W: Dose-ranging effects of canagliflozin, a so-
dium-glucose co-transporter 2 inhibitor, as 
add-on to metformin in subjects with type 2 
diabetes. Diabetes Care 2012; 35: 1232–1238. 
there was no difference across groups in upper UTIs. In-
cidences of genital mycotic infections in males and fe-
males were higher with both doses of canagliflozin com-
pared with placebo. However, these AEs were mild to 
moderate in intensity, generally did not lead to study drug 
discontinuation or interruption, and were treated by ei-
ther a healthcare professional or by the patient with either 
topical or oral antifungal agents. The incidence of frac-
ture AEs was not assessed in the current analysis, but a 
previous study in subjects with eGFR  ≥ 30 and <50 ml/
min/1.73 m 2 showed a low incidence of fractures with 
canagliflozin 100 and 300 mg and placebo, with no imbal-
ance between groups  [13] .
 The incidence of serum potassium elevation was in-
creased with canagliflozin 300 mg compared with placebo 
with no incremental changes observed with canagliflozin 
100 mg, the dosage indicated in patients with stage 3a CKD 
in the USA. In general, elevations in potassium were tran-
sient and did not require specific treatment. Significant el-
evations in serum potassium were uncommon and more 
frequently seen in patients with stage 3b CKD who received 
either the 300-mg dose, had elevated serum potassium 
concentrations prior to treatment, and/or were on multiple 
medications that reduce potassium excretion. However, 
there was no notable increase in incidence of hyperkale-
mia, i.e. serum potassium  ≥ 6.5 mEq/l with canagliflozin, 
even in the stage 3b CKD subgroup. Changes in potassium 
with canagliflozin did not appear related to changes in 
eGFR, blood urea nitrogen, or hemoglobin or to reduced 
intravascular volume. Of note, there were no other major 
electrolyte abnormalities associated with use of this drug.
 There are limitations to the analyses presented in that 
they represent pooled data and are drawn from cohorts 
that do not fully represent the cross section of ethnic 
groups with diabetic kidney disease, i.e. American- 
Indians, Asian-Pacific Islanders and relatively low num-
bers of African-Americans and Hispanics. Nevertheless, 
the data are consistent in both safety and efficacy and 
there is no mechanistic reason to think the response 
would be different in these underrepresented groups.
 In summary, the oral treatment options for T2DM pa-
tients with stage 3a CKD are limited to reduced doses of 
either metformin, peroxisome proliferator-activated 
receptor-γ agents, or dipeptidyl peptidase 4 inhibitors 
 [25] . Insulin and sulfonylureas may lead to weight gain, 
edema, or hypoglycemia. Certain SGLT2 inhibitors, 
namely canagliflozin, provide a new treatment option to 
help achieve glycemic control in T2DM patients with 
stage 3a CKD. The medication is well tolerated overall 
with the most common AEs relating to genital mycotic 
infections and enhanced risk of intravascular volume re-
duction, the latter also occurring in patients aged  ≥ 75 
years, and on loop diuretics. The effects of canagliflozin 
on CKD progression in man is currently being studied 
in  the Canagliflozin and Renal Events in Diabetes with 
 Established Nephropathy Clinical Evaluation Trial 
 (CREDENCE)  [26] . The results will provide the answer 
as to whether SGLT2 inhibition slows nephropathy pro-
gression.
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